IL13 receptor α2 signaling requires a scaffold protein, FAM120A, to activate the FAK and PI3K pathways in colon cancer metastasis

Cancer Research

Volumn 75, Issue 12, 2015, Pages 2434-2444

  Bartolomé, Rubén A ^a   García Palmero, Irene ^a   Torres, Sofía ^a   López Lucendo, María ^a   Balyasnikova, Irina V ^b   Casal, J Ignacio ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FAM120A; SCAFFOLD PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; FAM120A PROTEIN, HUMAN; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN-13 RECEPTOR, HUMAN; INTERLEUKIN-13, HUMAN; RNA BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; BINDING AFFINITY; CELL ADHESION; CELLULAR DISTRIBUTION; COLLISIONALLY ACTIVATED DISSOCIATION; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; LIVER METASTASIS; MICROTUBULE; MOUSE; NONHUMAN; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING; ANIMAL; COLON TUMOR; GENETIC TRANSFECTION; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; COLONIC NEOPLASMS; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HETEROGRAFTS; HUMANS; INTERLEUKIN-13; MICE; MICE, NUDE; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, INTERLEUKIN-13; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84941744518     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3650     Document Type: Article

References (28)

1. Wills-Karp M, Finkelman FD. Untangling the complex web of IL4- and IL13-mediated signaling pathways. Sci Signal 2008; 1: pe55.
2. Barderas R, Bartolome RA, Fernandez-Acenero MJ, Torres S, Casal JI. High expression of IL13 receptor alpha2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. Cancer Res 2012; 72: 2780-90.
3. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999; 5: 985-90.
4. Fujisawa T, Joshi B, Nakajima A, Puri RK. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res 2009; 69: 8678-85.
5. Bernard J, Treton D, Vermot-Desroches C, Boden C, Horellou P, Angevin E, et al. Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Ralpha2 as a decoy receptor for IL13. Lab Invest 2001; 81: 1223-31.
6. Beard RE, Abate-Daga D, Rosati SF, Zheng Z, Wunderlich JR, Rosenberg SA, et al. Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin Cancer Res 2013; 19: 4941-50.
7. Takenouchi M, Hirai S, Sakuragi N, Yagita H, Hamada H, Kato K. Epigenetic modulation enhances the therapeutic effect of anti-IL13R (alpha)2 antibody in human mesothelioma xenografts. Clin Cancer Res 2011; 17: 2819-29.
8. Kawakami M, Kawakami K, Kasperbauer JL, Hinkley LL, Tsukuda M, Strome SE, et al. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res 2003; 9: 6381-8.
9. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 2006; 107: 1407-18.
10. Hallett MA, Venmar KT, Fingleton B. Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL4 and IL13. Cancer Res 2012; 72: 6338-43.
11. Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ. IL13R(alpha)2, a decoy receptor for IL13 acts as an inhibitor of IL4-dependent signal transduction in glioblastoma cells. Cancer Res 2002; 62: 1103-9.
12. Mandal D, Levine AD. Elevated IL13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway. Inflamm Bowel Dis 2010; 16: 753-64.
13. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL13 signaling through the IL13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12: 99-106.
14. Bartolome RA, Galvez BG, Longo N, Baleux F, Van Muijen GN, Sanchez-Mateos P, et al. Stromal cell-derived factor-1alpha promotes melanoma cell invasion across basement membranes involving stimulation of mem-brane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res 2004; 64: 2534-43.
15. Mellacheruvu D, Wright Z, Couzens AL, Lambert JP, St-Denis NA, Li T, et al. The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Nat Methods 2013; 10: 730-6.
16. Tanaka M, Sasaki K, Kamata R, Hoshino Y, Yanagihara K, Sakai R. A novel RNA-binding protein, Ossa/C9orf10, regulates activity of Src kinases to protect cells from oxidative stress-induced apoptosis. Mol Cell Biol 2009; 29: 402-13.
17. Balyasnikova IV, Wainwright DA, Solomaha E, Lee G, Han Y, Thaci B, et al. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor alpha2. J Biol Chem 2012; 287: 30215-27.
18. Toutant M, Costa A, Studler JM, Kadare G, Carnaud M, Girault JA. Alternativesplicing controls the mechanisms of FAKautophosphorylation. Mol Cell Biol 2002; 22: 7731-43.
19. Lipfert L, Haimovich B, Schaller MD, Cobb BS, Parsons JT, Brugge JS. Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets. J Cell Biol 1992; 119: 905-12.
20. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.
21. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004; 90: 561-5.
22. Dhanasekaran DN, Kashef K, Lee CM, Xu H, Reddy EP. Scaffold proteins of MAP-kinase modules. Oncogene 2007; 26: 3185-202.
23. Kelkar N, Delmotte MH, Weston CR, Barrett T, Sheppard BJ, Flavell RA, et al. Morphogenesis of the telencephalic commissure requires scaffold protein JNK-interacting protein 3 (JIP3). Proc Natl Acad Sci U S A 2003; 100: 9843-8.
24. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2: 241-3.
25. Hameed AG, Arnold ND, Chamberlain J, Pickworth JA, Paiva C, Dawson S, et al. Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med 2012; 209: 1919-35.
26. Luo R, Jeong SJ, Yang A, Wen M, Saslowsky DE, Lencer WI, et al. Mechanism for adhesion G protein-coupled receptor GPR56-mediated RhoA activation induced by collagen III stimulation. PLoS ONE 2014; 9: e100043.
27. Leve F, Morgado-Diaz JA. Rho GTPase signaling in the development of colorectal cancer. J Cell Biochem 2012; 113: 2549-59.
28. Struckhoff AP, Rana MK, Worthylake RA. RhoA can lead the way in tumor cell invasion and metastasis. Front Biosci 2011; 16: 1915-26.